Role of maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced

摘要

PurposeChemokines and their receptors play a crucial role in the development of atherosclerosis. CCR5 is considered to be crucial to monocyte recruitment during development of atherosclerosis. CCR5, known as a co-receptor of HIV-1, is the target of the approved CCR5 antagonist maraviroc (MVC). Therefore we investigated whether MVC reduces inflammation and atherosclerosis in a rodent model of dyslipidemia (ApoE-/-mice) treated or not with Ritonavir (RTV).